Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study Before HCT, 88 patients met morphologic criteria for complete remission (CR), ...

The press release below was prepared by the American Association for Cancer Research. View the original here. Next-generation sequencing for minimal residual disease was highly sensitive and more ...

Minimal residual disease (MRD) has emerged as a significant marker in the treatment of multiple myeloma (MM), allowing clinicians to make more informed decisions about therapy. MRD testing helps gauge ...

Five hundred forty-two specimens of 150 children enrolled in the AML-Berlin-Frankfurt-Muenster (BFM) 98 study were analyzed by four-color immunophenotyping at up to four predefined time points during ...

Please could you both introduce yourselves and give a brief outline of your roles at Cerba Research? ADB: My name is Ans De Beuckelaer. I have a Ph.D. in biotechnology from the University of Ghent. In ...

Although minimal residual disease (MRD) has emerged as a valuable prognostic marker across several hematological malignancies, its use in chronic lymphocytic leukemia (CLL) is mostly limited to ...

In part 2 of our interview with Surbhi Sidana, MD, MBBS, American Society of Hematology and Stanford University, she delves into one of the hottest topics in the hematologic malignancy space today: ...

Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, in partnership with Rarity Bioscience AB offers a new approach to oncology research by extending the ...

Invivoscribe Inc., a global leader in precision diagnostics and measurable residual disease (MRD) testing, is proud to support CERo Therapeutics Holdings, Inc., an innovative immunotherapy company ...

Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial Invivoscribe Inc., a ...